

Rosamonde Elizabeth Banks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2414866/publications.pdf>

Version: 2024-02-01

43
papers

2,272
citations

331538

21
h-index

302012

39
g-index

46
all docs

46
docs citations

46
times ranked

4279
citing authors

#	ARTICLE	IF	CITATIONS
1	The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis – Preliminary findings. <i>Electrophoresis</i> , 1999, 20, 689-700.	1.3	287
2	Genetic and Epigenetic Analysis of von Hippel-Lindau (VHL) Gene Alterations and Relationship with Clinical Variables in Sporadic Renal Cancer. <i>Cancer Research</i> , 2006, 66, 2000-2011.	0.4	259
3	Influences of Blood Sample Processing on Low-Molecular-Weight Proteome Identified by Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry. <i>Clinical Chemistry</i> , 2005, 51, 1637-1649.	1.5	225
4	Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. <i>Nature Genetics</i> , 2011, 43, 60-65.	9.4	220
5	Variation in genomic landscape of clear cell renal cell carcinoma across Europe. <i>Nature Communications</i> , 2014, 5, 5135.	5.8	158
6	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , 2017, 8, 15724.	5.8	106
7	A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. <i>Human Molecular Genetics</i> , 2012, 21, 456-462.	1.4	81
8	CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	75
9	Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. <i>Journal of Proteomics</i> , 2014, 98, 44-58.	1.2	64
10	Measurement of Cytokines in Clinical Samples Using Immunoassays: Problems and Pitfalls. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2000, 37, 131-182.	2.7	61
11	The influence of obesity-related factors in the etiology of renal cell carcinoma – A mendelian randomization study. <i>PLoS Medicine</i> , 2019, 16, e1002724.	3.9	59
12	A General Framework for Interrogation of mRNA Stability Programs Identifies RNA-Binding Proteins that Govern Cancer Transcriptomes. <i>Cell Reports</i> , 2018, 23, 1639-1650.	2.9	56
13	Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. <i>BMJ Open</i> , 2020, 10, e035938.	0.8	54
14	Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma. <i>Scientific Reports</i> , 2017, 7, 44876.	1.6	42
15	Aristolochic acid exposure in Romania and implications for renal cell carcinoma. <i>British Journal of Cancer</i> , 2016, 114, 76-80.	2.9	39
16	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 747-754.	0.9	39
17	Sex specific associations in genome wide association analysis of renal cell carcinoma. <i>European Journal of Human Genetics</i> , 2019, 27, 1589-1598.	1.4	27
18	Use of a sensitive EnVision, Æ+-based detection system for Western blotting: avoidance of streptavidin binding to endogenous biotin and biotin-containing proteins in kidney and other tissues. <i>Proteomics</i> , 2003, 3, 558-561.	1.3	26

#	ARTICLE	IF	CITATIONS
19	Key clinical issues in renal cancer: a challenge for proteomics. <i>World Journal of Urology</i> , 2007, 25, 537-556.	1.2	25
20	Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab. <i>British Journal of Cancer</i> , 2016, 115, 228-235.	2.9	23
21	Urological malignancies and the proteomic-genomic interface. <i>Electrophoresis</i> , 1999, 20, 3629-3637.	1.3	22
22	Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol. <i>BMC Nephrology</i> , 2020, 21, 242.	0.8	22
23	PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 1102.	1.1	17
24	Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion. <i>British Journal of Cancer</i> , 2020, 123, 137-147.	2.9	17
25	Detergent-Free Simultaneous Sample Preparation Method for Proteomics and Metabolomics. <i>Journal of Proteome Research</i> , 2020, 19, 2838-2844.	1.8	16
26	An analysis of the impact of pre-analytical factors on the urine proteome: Sample processing time, temperature, and proteolysis. <i>Proteomics - Clinical Applications</i> , 2015, 9, 507-521.	0.8	15
27	Biomarkers During Recovery From AKI and Prediction of Long-term Reductions in Estimated GFR. <i>American Journal of Kidney Diseases</i> , 2022, 79, 646-656.e1.	2.1	15
28	Renal carcinoma cell lines inhibit natural killer activity via the CD94 receptor molecule. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 260-268.	2.0	13
29	UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time. <i>Urology</i> , 2020, 136, 162-168.	0.5	12
30	C-STrap Sample Preparation Method—In-Situ Cysteinyl Peptide Capture for Bottom-Up Proteomics Analysis in the STrap Format. <i>PLoS ONE</i> , 2015, 10, e0138775.	1.1	11
31	Bone Alkaline Phosphatase in Rheumatic Diseases. <i>Annals of Clinical Biochemistry</i> , 1995, 32, 379-384.	0.8	7
32	Aberration hubs in protein interaction networks highlight actionable targets in cancer. <i>Oncotarget</i> , 2018, 9, 25166-25180.	0.8	6
33	A simple serum depletion method for proteomics analysis. <i>BioTechniques</i> , 2020, 69, 148-151.	0.8	5
34	Oncogene-induced cellular senescence elicits an anti-Warburg effect. <i>Proteomics</i> , 2013, 13, 2542-2543.	1.3	2
35	Urological malignancies and the proteomic-genomic interface. <i>Electrophoresis</i> , 1999, 20, 3629-3637.	1.3	2
36	Protein Biomarker Research in UK Hospital Clinical Biochemistry Laboratories: A Survey of Current Practice and Views. <i>Clinical Biochemist Reviews</i> , 2014, 35, 115-33.	3.3	2

#	ARTICLE	IF	CITATIONS
37	Morphological findings in frozen non-neoplastic kidney tissues of patients with kidney cancer from large-scale multicentric studies on renal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 1099-1107.	1.4	1
38	An Exploratory Analysis of Changes in Circulating Plasma Protein Profiles Following Image-Guided Ablation of Renal Tumours Provides Evidence for Effects on Multiple Biological Processes. <i>Cancers</i> , 2021, 13, 6037.	1.7	1
39	Unravelling Biological Pathways and the Identification of Clinical Markers and Targets in Renal Cancer. , 2004, , 73-96.		0
40	Proteomic Analysis of Primary and Established Cell Lines for the Investigation of Renal Cell Carcinoma. , 0, , 149-166.		0
41	AUTHOR REPLY. <i>Urology</i> , 2020, 136, 168.	0.5	0
42	Abstract LB113: Genomic classification to refine prognosis in clear cell renal cell carcinoma. <i>Cancer Research</i> , 2022, 82, LB113-LB113.	0.4	0
43	Bio-miR: A prognostic microRNA-based signature for localized clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16519-e16519.	0.8	0